The experimental system focused on the widely studied JAK2V617F mutation. JAK2 is an enzyme that normally transmits signals from cytokine receptors to the cell nucleus, helping regulate blood-cell production. The V617F mutation changes a single DNA base, producing a permanently active version of the enzyme. Instead of responding only when instructed by external growth signals, mutant JAK2 can continuously stimulate pathways that promote cell survival and proliferation. The mutation is found in many cases of polycythemia vera and in a substantial fraction of essential thrombocythemia and myelofibrosis, disorders in which excessive blood-cell production and persistent inflammation can contribute to clotting, bone-marrow scarring and disease progression.

The researchers explored whether spherical gold nanoparticles could be used to interfere with this abnormal biology while also altering the cells’ response to genetic material. Each particle was about 13 nanometres across before it was coated with strands of DNA-like oligonucleotides, producing a final construct roughly 25 nanometres in diameter. The attached sequences were designed to pair with messenger RNA encoding either normal JAK2 or the JAK2V617F mutant. Pairing an oligonucleotide with its complementary messenger RNA can destabilize the transcript or hinder its translation, potentially reducing production of the corresponding protein. Gold nanoparticles are useful carriers because dense layers of nucleic acids on their surfaces can improve stability and promote uptake through endocytosis, the process by which cells engulf material into membrane-bound compartments.

The team treated three human cell lines with the constructs at a concentration of 200 picomolar and measured their responses over intervals ranging from 30 minutes to 72 hours. HEL cells carry two copies of JAK2V617F and resemble aspects of polycythemia vera. SET2 cells carry one mutant copy and are used as a model related to essential thrombocythemia. K562 cells, included as a comparison, lack JAK2V617F and instead carry the BCR-ABL fusion associated with chronic myeloid leukemia. The researchers also used nanoparticles bearing scrambled oligonucleotide sequences that were not designed to match any cellular transcript. Gene activity was assessed using quantitative reverse-transcription PCR, while receptor proteins were examined by flow cytometry and secreted inflammatory molecules were measured in the culture medium.

The most dramatic pattern emerged in pathways that detect nucleic acids, the molecular material of DNA and RNA. TLR9 is an intracellular receptor that recognizes DNA containing particular CpG motifs and can activate inflammatory transcription programs. One of its downstream regulators is IRF7, a transcription factor that helps drive type I interferon responses, while NF-κB, represented in the study by the NFKB1 gene, controls a broad range of inflammatory and survival-related genes. Following nanoparticle exposure, these systems showed little change during the first few hours, but their activity shifted later. TLR9 expression rose sharply in SET2 cells after 24 and 48 hours, reaching approximately 200- to 300-fold above control levels before falling toward baseline by 72 hours. The response did not clearly depend on whether the attached sequence targeted normal JAK2, mutant JAK2 or neither.

IRF7 displayed an even stronger mutation-associated response. In HEL cells, nanoparticles directed against JAK2V617F produced an approximately 20-fold increase in IRF7 expression at later time points. In SET2 cells, the increase approached 100-fold. These effects were much more pronounced than in the JAK2V617F-negative K562 line, suggesting that the mutant signaling environment altered how cells processed or responded to the nanoparticle-bound oligonucleotides. NFKB1 also increased after longer exposure, particularly in HEL and SET2 cells, where JAK2- and JAK2V617F-targeting particles produced roughly tenfold increases at 24 or 48 hours. K562 cells responded later and less consistently, reinforcing the idea that the nanoparticles were not acting through a single universal mechanism.

The second major surveillance system, known as cGAS-STING, responded in a similarly complicated fashion. cGAS detects DNA that appears in the cell’s cytoplasm, where it normally should not be. Once activated, it produces the small messenger molecule cyclic GMP-AMP, which binds to STING on the endoplasmic reticulum. STING then recruits the kinase TBK1, leading to activation of IRF3 and production of interferons and other inflammatory signals. In the experiments, cGAS expression generally increased after prolonged nanoparticle treatment, including in all three cell lines under at least some conditions. Yet STING did not rise in parallel. In K562 cells, for example, cGAS was strongly induced while STING showed little obvious response. This mismatch suggests that increasing the amount of cGAS does not necessarily activate the entire pathway; protein modification, degradation, trafficking or epigenetic repression may determine whether STING can transmit the signal.

The researchers also investigated RAGE, a receptor that can assist the delivery of extracellular nucleic acids into endosomes, the compartments where TLR9 is located. If the nanoparticles were activating TLR9 through a RAGE-dependent route, changes in RAGE protein might have been expected. Instead, flow-cytometry measurements in HEL cells found no significant changes in either surface or intracellular RAGE after short or long exposure to JAK2- or JAK2V617F-targeting particles. Intracellular TLR9 protein levels also remained largely unchanged, even when TLR9 messenger RNA increased. This distinction between RNA and protein is biologically important. Gene expression measured by PCR indicates that a transcript is more abundant, but it does not guarantee that more receptor will be produced. Messenger RNAs can be stabilized, trapped by RNA-binding proteins, transported differently or prevented from being efficiently translated. The result suggests that the delayed inflammatory response may be controlled downstream of transcription or through a pathway that does not require RAGE.

Cytokine measurements supplied a functional readout of the molecular changes. The investigators tested a broad panel that included interferons, tumour-necrosis factor, interleukins and the chemokine MCP-1, but IL-8, also called CXCL8, was the most notable signal. IL-8 levels increased in media from the JAK2V617F-positive HEL and SET2 cultures after extended treatment, with HEL cells showing a particularly strong response and a peak reported around 48 hours for some nanoparticle conditions. IL-8 attracts and activates immune cells and has been associated in myeloproliferative neoplasms with leukocytosis, thrombosis and bone-marrow fibrosis. Its induction therefore underscores both the therapeutic promise and the potential hazard of the approach: a particle intended to dampen pathological inflammation could, after a delay, stimulate inflammatory outputs depending on dose, sequence and cellular context.

The authors describe this behaviour as a biphasic response. In the short term, oligonucleotide-coated gold nanoparticles can suppress components of TLR9, IRF7 and related signaling networks, potentially reducing inflammatory activity. Over the following day or two, however, the same treatment can provoke increased expression of IRF7, TLR9, cGAS or NF-κB-associated genes, especially in cells carrying JAK2V617F. Such timing could reflect nanoparticle trafficking through endosomes, gradual release or processing of the attached oligonucleotides, delayed feedback from interferon signaling, or compensatory responses to attempted JAK2 suppression. The investigators emphasize that the effects were not always sequence-specific: scrambled nanoparticles sometimes produced comparable changes, raising the possibility that the gold core, the nucleic-acid coating or cellular uptake itself contributes to the response.

That complexity means the study is better viewed as a molecular map than as evidence of a ready-to-use treatment. The experiments used only three established cell lines, each with distinct origins and signaling abnormalities, and relied on a small number of replicate wells and PCR runs. The work did not demonstrate that the nanoparticles reduced cell proliferation, eliminated mutant clones or improved disease features in an organism. It also did not establish how the particles would distribute through the body, whether they would accumulate in the liver or spleen, how long they would persist, or whether they would trigger unwanted immune reactions. Before clinical testing, researchers will need to identify the precise mechanisms behind the early suppression and delayed activation, define safe exposure windows, test primary patient cells and evaluate toxicity in animal models.

Even so, the results highlight an emerging strategy in precision medicine: targeting not only an oncogenic mutation but also the inflammatory circuitry that sustains blood cancer. Because JAK2V617F-positive cells showed distinct IRF7 responses from mutation-negative cells, future nanoparticle designs might be tailored to particular genetic and disease subtypes. They could potentially be combined with existing JAK inhibitors, which block aberrant signaling but do not always eliminate the malignant clone or fully control inflammation. The immediate challenge is to turn the nanoparticles’ unpredictable timing into a controllable feature. If researchers can preserve the initial dampening effect while preventing the later inflammatory rebound, gold-bound oligonucleotides may become a versatile platform for modulating nucleic-acid sensing in myeloproliferative neoplasms and other inflammation-driven cancers.

Subject of Research: Oligonucleotide-coated gold nanoparticles and their effects on nucleic-acid sensing, inflammatory signaling and cytokine production in JAK2V617F-positive myeloproliferative neoplasm cell models

Article Title: Suppressed activation of the IRF7 and TLR9 by JAK2V617F gold nanoparticles

Article References: Tokcan, B., Demirtaş, E.N. & Sözer, S. “Suppressed activation of the IRF7 and TLR9 by JAK2V617F gold nanoparticles.” Immunogenetics 77, 16 (2025). Original research article

Image Credits: AI Generated

DOI: 10.1007/s00251-025-01374-y

Keywords: JAK2V617F, gold nanoparticles, oligonucleotide delivery, TLR9, IRF7, cGAS-STING, IL-8, myeloproliferative neoplasms

Cellular senescence is a natural response to severe stress, including DNA damage, oncogene activation, and treatment with certain anticancer drugs. When a cell becomes senescent, molecular brakes lock the cell cycle, preventing further division. This arrest is often considered beneficial because it stops damaged or malignant cells from multiplying. However, senescent cells do not simply shut down. They can continue producing proteins, reorganizing their internal structure, and secreting a collection of cytokines, growth factors, enzymes, and other molecules known collectively as the senescence-associated secretory phenotype, or SASP. The SASP can influence immune cells and neighboring tissues, sometimes promoting repair and clearance, but persistent SASP activity can also drive inflammation and alter the tumor microenvironment.

The Rockefeller team, led by Viviana I. Risca, compared two cancer therapies that induce senescence through substantially different mechanisms. The researchers used laboratory models of liposarcoma and estrogen receptor-positive breast cancer. One treatment was doxorubicin, a chemotherapy drug that damages DNA and triggers a well-established DNA damage response. The other was palbociclib, a CDK4/6 inhibitor used clinically against several cancers. Palbociclib blocks the activity of cyclin-dependent kinases 4 and 6, enzymes that help cells pass through the cell cycle. By preventing this transition, the drug can impose prolonged growth arrest without directly producing the extensive DNA damage associated with doxorubicin.

The researchers tracked the treated cancer cells for nearly a month, combining genomic, epigenomic, and imaging methods to observe how their behavior changed over time. This extended analysis revealed that senescence develops along a trajectory rather than appearing instantaneously. The cells first activated signals associated with tissue remodeling, followed weeks later by a stronger inflammatory program. The timing was particularly important for cells exposed to palbociclib. Earlier studies that examined only short treatment windows had largely missed the delayed inflammatory phase, creating the impression that the response to CDK4/6 inhibition was either weaker or fundamentally different from the response to DNA-damaging chemotherapy.

Although doxorubicin and palbociclib initiated senescence by different routes, the two treatments eventually converged on a common inflammatory pathway controlled by the transcription factor NF-κB. NF-κB regulates the expression of numerous genes involved in inflammation, immune signaling, cell survival, and tissue remodeling. In doxorubicin-treated cells, DNA damage activated sensors that rapidly stimulated NF-κB. Palbociclib-treated cells, by contrast, did not require a major DNA damage response. Their early tissue-remodeling signals appeared to activate receptors at the cell surface, which gradually transmitted signals inward and ultimately engaged NF-κB. In this way, the two therapies followed separate molecular paths before reaching a similar inflammatory destination.

The distinction was confirmed experimentally by blocking the cells’ DNA damage sensors. This intervention reduced inflammatory signaling in doxorubicin-treated cells, consistent with the drug’s direct effects on DNA. It did not suppress the corresponding response in palbociclib-treated cells, demonstrating that the CDK4/6 inhibitor uses a different signaling route. The observation challenges the assumption that DNA damage is always the central trigger of the inflammatory SASP. Instead, the findings indicate that senescent cells can assemble overlapping features through distinct molecular mechanisms, with the final inflammatory response shaped by the treatment’s initial effects and the time elapsed after exposure.

The study also provided a detailed view of the epigenetic changes that accompany senescence. Epigenetics refers to the molecular systems that control gene activity without altering the underlying DNA sequence. The researchers found that inflammatory genes became accessible through changes in regulatory regions called enhancers, which act as switches that increase gene transcription. They also observed the loss of macroH2A, a chromatin-associated protein that helps organize DNA and regulate access to genetic information. When chromatin structure changes, previously restricted genes can become active. These alterations help explain how senescent cells maintain long-term growth arrest while simultaneously acquiring the ability to produce an increasingly complex set of inflammatory signals.

A crucial result was that the researchers could inhibit NF-κB and reduce inflammatory signaling without restoring the cancer cells’ ability to divide. This suggests that growth arrest and inflammatory activity, although both associated with senescence, are separable biological programs. In practical terms, a therapy designed to suppress the SASP might limit the harmful effects of treatment-induced senescence without “waking up” the arrested tumor cells. Such an approach could be especially valuable in cancers treated with CDK4/6 inhibitors, where senescence may persist for extended periods and continue influencing the surrounding tissue after the initial drug exposure.

The findings offer a framework for developing combination therapies that target both tumor growth and the consequences of cellular senescence. Rather than treating senescence as a binary state—either present or absent—clinicians and researchers may eventually need to consider its timing, molecular route, and secretory profile. Blocking inflammatory signals too early could interfere with beneficial immune responses, while allowing them to persist could contribute to tumor-supportive inflammation. The researchers emphasize that further studies will be needed to determine whether the same sequence occurs in patients and whether NF-κB-targeting strategies can be safely combined with existing cancer treatments. Even so, the work provides a detailed molecular map of how therapy-induced senescence unfolds and identifies a potential route to retain the anti-cancer effects of cellular arrest while limiting the signals that could promote disease later.

Subject of Research: Cellular senescence, therapy-induced inflammation, cancer treatment, the senescence-associated secretory phenotype, and NF-κB signaling in liposarcoma and estrogen receptor-positive breast cancer.

Article Title: The specific article title was not provided in the source content.

Web References: Life Science Alliance article; Viviana I. Risca laboratory profile; Laboratory of Genome Architecture and Dynamics.

References: Life Science Alliance, DOI: 10.26508/lsa.202603790.

Image Credits: Lori Chertoff/The Rockefeller University.

Keywords: Cancer, cellular senescence, senescence-associated secretory phenotype, SASP, inflammation, NF-κB, CDK4/6 inhibitors, palbociclib, doxorubicin, DNA damage, liposarcoma, breast cancer, epigenetics, tumor microenvironment.

Elenagen’s mechanism of action diverges fundamentally from conventional chemotherapeutic paradigms. By encoding the multifunctional protein p62/SQSTM1, Elenagen influences the tumor microenvironment to mitigate chronic inflammation and enhance immune cell infiltration. This recalibration curbs tumor immune suppression and metastasis, leveraging the tumor cells’ intrinsic dependence on p62 as an immune target. Unlike therapies that merely intensify cytotoxic assault, Elenagen fosters an immunological milieu that supports endogenous anti-cancer processes, potentially revolutionizing therapeutic paradigms for ovarian and other solid tumors.

The randomized Phase II clinical trial, recently published in the International Journal of Gynecological Cancer, encompassed women with platinum-resistant disease exhibiting elevated CA-125 levels, a subgroup associated with the direst prognostic outcomes. In this rigorous study, participants receiving the Elenagen and gemcitabine regimen demonstrated a median overall survival exceeding 25 months—nearly doubling the approximately 13 months observed with chemotherapy alone. This staggering enhancement corresponds with an approximate 60% reduction in mortality risk, a transformative improvement that reframes expectations for this patient cohort.

Crucially, Elenagen’s therapeutic gains emerged without an accompanying increase in treatment-related toxicity. This favorable safety profile underscores the therapy’s tolerability and positions it as a promising adjunct without exacerbating the often burdensome side effects typical of cancer treatments. Equally remarkable are the long-term responders, some surviving years beyond predicted outcomes, underscoring the potential durability of Elenagen’s clinical benefit.

Insights gleaned from an unplanned treatment interruption due to geopolitical factors revealed a striking dose-duration response: longer exposure to Elenagen correlated with prolonged survival after discontinuation. These data suggest the current survival benefit estimates may be conservative, bolstering the rationale to extend therapy duration in ongoing and future trials. Plans are underway to evaluate Elenagen administration for up to 24 months, aiming to maximize therapeutic efficacy and patient outcomes in forthcoming U.S. and European studies.

The biological rationale for Elenagen’s efficacy extends beyond immunomodulation. The protein p62/SQSTM1 is integral to autophagy, oxidative stress responses, and oncogenic signaling pathways. Cancer cells’ overreliance on p62 creates a unique vulnerability; Elenagen’s plasmid DNA educates the immune system to recognize and target this protein, thus converting a tumor’s survival mechanism into an Achilles’ heel. This mechanism opens avenues not only for ovarian cancer but potentially other malignancies with p62 overexpression.

Dr. Alexander Shneider, CEO of CureLab Oncology and the inventor of Elenagen, emphasizes the evolutionary significance of this therapy. Originating as an experimental cancer vaccine, Elenagen has matured into a comprehensive adjuvant that addresses complex cancer biology via immune modulation and inflammation control. Its implications may transcend oncology, suggesting applications in diseases characterized by chronic inflammation and possibly aging—heralding a new class of DNA-based therapeutics with broad clinical potential.

Ovarian cancer remains one of the deadliest gynecologic cancers worldwide, affecting roughly one in eighty women during their lifetime. The recurrent nature of the disease, coupled with the development of platinum resistance, relegates patients to therapies with limited efficacy and significant side effects, often measured in mere months of survival. This stark reality underscores the urgent need for innovative treatments like Elenagen that challenge the existing therapeutic inertia.

With regulatory guidance and collaborative efforts alongside institutions such as the Gynecologic Oncology Group (GOG) Foundation, CureLab Oncology is advancing Phase II/III trials, aiming to solidify Elenagen’s clinical utility both in platinum-resistant ovarian cancer and aggressive breast cancer subtypes. These trials will incorporate comprehensive quality of life assessments, a critical dimension often underexplored yet paramount to patient-centered care, particularly for treatments modulating chronic inflammation.

The convergence of molecular innovation, immuno-oncology, and clinical rigor embodied by Elenagen heralds a hopeful horizon for patients enduring the formidable challenge of platinum-resistant ovarian cancer. By harnessing the intricate interplay of tumor biology and immune regulation, Elenagen exemplifies a transformative therapeutic paradigm—one that holds promise not only to extend life but also to enhance its quality.

In summary, Elenagen represents a groundbreaking development emerging from the intersection of advanced molecular medicine and immune modulation. Its capacity to double median survival without augmenting toxicity challenges conventional oncologic wisdom and sparks optimism for future therapies targeting tumor microenvironment and chronic inflammation. As clinical trials progress, the oncology community eagerly anticipates validation of these compelling results, potentially marking a pivotal shift in the management of refractory ovarian cancer.

Subject of Research: Investigational DNA therapy Elenagen (p62/SQSTM1-encoding plasmid) combined with gemcitabine for platinum-resistant ovarian cancer

Article Title: Randomized Phase II Study of P62/Sqstm1-Encoding Plasmid (Elenagen) In Combination With Gemcitabine for Platinum-Resistant Ovarian Cancer

News Publication Date: Prior to February 27, 2026 (conference presentation date)

Web References:

• CureLab Oncology: https://www.curelaboncology.com/
• International Journal of Gynecological Cancer article: https://www.international-journal-of-gynecological-cancer.com/article/S1048-891X(25)03580-7/fulltext

Image Credits: CureLab Oncology

Keywords: Ovarian cancer, platinum-resistant ovarian cancer, Elenagen, p62/SQSTM1, DNA therapy, immunotherapy, gemcitabine, tumor microenvironment, chronic inflammation, clinical trial, gynecologic oncology

Central among these discoveries is the revelation that intestinal metabolism critically governs the regeneration and differentiation of intestinal stem cells, a process vital for maintaining gut integrity. The intestinal lining is one of the most rapidly renewing tissues in mammals, with stem cells continuously differentiating to replenish diverse cell types needed for nutrient absorption and microbial defense. MSK researchers used sophisticated genetically engineered mouse models and three-dimensional organoid cultures to dissect how specific metabolites influence the fate decisions of these stem cells within living organisms. Their work highlights alpha-ketoglutarate, a key metabolite traditionally recognized for its role in cellular energy cycles, as a pivotal signaling molecule orchestrating stem cell differentiation toward protective intestinal cell lineages.

This nuanced function of alpha-ketoglutarate reshapes our understanding of metabolic regulation in tissue regeneration. Beyond merely fueling bioenergetic demands, such metabolites appear to act as molecular directors, actively shaping cell identity and tissue architecture during regeneration. In mouse models mimicking ulcerative colitis, a chronic inflammatory disease that compromises intestinal barrier function, supplementation with alpha-ketoglutarate restored deficient differentiation pathways and accelerated mucosal healing. This finding carries substantial weight, as chronic inflammation is a recognized precursor to colorectal cancer. Thus, modulating metabolic pathways to enhance stem cell-driven tissue repair not only offers therapeutic avenues for inflammatory bowel diseases but also for cancer prevention.

Previous investigations by the same lab have implicated alpha-ketoglutarate in enhancing the tumor-suppressive function of p53, the “guardian of the genome.” Given that p53 dysfunction is common in pancreatic and other cancers, boosting alpha-ketoglutarate levels may offer a metabolic approach to reinstate tumor suppression. Taken together, these insights reveal a dual role for metabolites in both maintaining tissue homeostasis and restraining oncogenesis, forging new paths in regenerative medicine and metabolic oncology.

Shifting focus to breast cancer, MSK scientists have uncovered a molecular mechanism driving resistance to hormonal and targeted therapies, mediated by the APOBEC3 family of enzymes. While APOBEC3 proteins are chiefly recognized for their antiviral defenses—inducing mutations to disrupt viral genomes—emerging evidence implicates their mutagenic activity in cancer evolution. Analyzing nearly four thousand patient tumor samples, the research team identified distinct mutational signatures attributable to APOBEC3 enzymes. Crucially, these mutational patterns correlated with shortened progression-free survival among patients undergoing endocrine and targeted treatments, highlighting APOBEC3 activity as a biomarker and contributor to therapeutic failure.

One pivotal mutation linked to APOBEC3-mediated mutagenesis is the loss of RB1, a tumor suppressor gene integral to cell cycle regulation. The accumulation of these mutations fosters genomic instability, enabling cancer cells to evade growth controls and resist therapy. Notably, the presence of APOBEC3-induced changes in pre-treatment tumors underscores their role not only in resistance development but also in the initiation and progression of malignancy. These findings elevate APOBEC3 enzymes as promising targets for therapeutic intervention, potentially disrupting the mutational processes that fuel breast cancer resilience.

In a complementary study probing resistance mechanisms in estrogen receptor-positive (ER+) breast cancer, researchers employed CRISPR-Cas9 genetic screening to spotlight NR2F2, a transcription factor implicated in suppressing estrogen receptor signaling. Endocrine therapies, fundamental to managing ER+ breast cancer, function by blocking estrogen-driven proliferation. However, resistance frequently arises, undermining treatment efficacy. The discovery that NR2F2 modulates gene networks to dampen ER signaling clarifies one pathway through which tumors circumvent hormonal intervention.

Functional assays using patient-derived tumor models demonstrated that pharmacological inhibition or genetic ablation of NR2F2 restored sensitivity to endocrine therapies. This breakthrough paves the way for novel therapeutic combinations that could resensitize resistant tumors by targeting NR2F2-mediated transcriptional repression. Such precision medicine strategies promise to extend the durability of current hormonal treatments and improve patient survival.

Beyond molecular and cellular investigations, MSK’s clinical research has explored integrative therapies to alleviate treatment-related side effects in cancer survivors. A randomized pilot trial evaluated acupuncture’s efficacy in mitigating nocturia—a distressing condition characterized by frequent nighttime urination, which is highly prevalent among men treated for prostate cancer. This condition disrupts sleep and erodes quality of life, often persisting years after cancer treatment completion. The trial enrolled 60 men with a history of varied prostate cancer therapies, including surgery, radiation modalities, and hormone therapy.

Participants randomized to a regimen of weekly acupuncture sessions for ten weeks exhibited a significant reduction in nocturnal urination frequency compared to controls receiving standard care. On average, acupuncture recipients woke up approximately one less time per night, with benefits sustained beyond the intervention period. Importantly, no serious adverse events were associated with the acupuncture treatments. This pilot study offers encouraging evidence supporting acupuncture as a safe, non-pharmacological option to improve urinary symptoms and sleep quality in prostate cancer survivors, meriting further investigation in larger, controlled trials.

Taken together, these multifaceted research advances from MSK embody a holistic approach to cancer science, integrating molecular biology, genetic engineering, metabolic biochemistry, and patient-centered clinical research. They unravel fundamental disease mechanisms while simultaneously advancing tangible therapeutic solutions—from metabolite-based tissue regeneration strategies and targeted inhibition of resistance drivers to integrative therapies enhancing survivorship. As these insights translate into clinical innovations, they hold promise to redefine standards of care across oncology disciplines.

Future research will undoubtedly delve deeper into the mechanistic intricacies unveiled by these studies, elucidating how metabolic cues intersect with genetic pathways to govern cancer initiation, progression, and response to treatment. Furthermore, translating findings regarding APOBEC3 and NR2F2 into targeted drug development could transform therapeutic landscapes, offering new hope for overcoming resistance in aggressive breast cancers. Meanwhile, integrating complementary modalities such as acupuncture into survivorship care exemplifies a patient-centered paradigm addressing the broad spectrum of symptoms experienced by cancer patients beyond tumor control.

Memorial Sloan Kettering’s continued commitment to pioneering interdisciplinary cancer research positions the field toward a future where precision-targeted metabolic modulation, genomic stability preservation, and holistic symptom management converge to optimize outcomes for millions affected by cancer worldwide.

Subject of Research: Cancer Biology and Therapeutics, Metabolic Regulation, Breast and Prostate Cancer Resistance, Integrative Oncology

Article Title: Metabolic Insight Reveals New Frontiers in Cancer Regeneration and Resistance

News Publication Date: 2024

Web References:

• https://www.nature.com/articles/s41586-025-09097-6
• https://www.nature.com/articles/s41588-025-02187-1
• https://www.science.org/doi/10.1126/scitranslmed.adk7786
• https://jamanetwork.com/journals/jamaoncology/article-abstract/2834640

References:

• Chaves-Perez, A., Millman, S., & Lowe, S.W. et al. (2024).
• Chandarlapaty, S. et al. (2024).

Image Credits: Memorial Sloan Kettering Cancer Center

Keywords: Cancer research, Basic research, Prostate cancer, Breast cancer